Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;1999(2):CD001418.
doi: 10.1002/14651858.CD001418.

Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group

L Stewart  1 ; Advanced Ovarian Cancer Trialists Group
Affiliations

Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group

L Stewart et al. Cochrane Database Syst Rev. 2000.

Abstract

Background: Ovarian carcinoma is the seventh most common cancer of women in the world and is responsible for the greatest number of deaths from gynaecological malignancy in Europe and North America. Although many studies have explored the use of chemotherapy in this disease, most individual trials have been too small to show clear benefit of one type of chemotherapy over another.

Objectives: The type and intensity of chemotherapy used routinely for women with advanced ovarian cancer has varied because of uncertainty about the effectiveness of the different regimens. The objective of this review was to compare single drugs versus combinations of drugs, platinum versus non-platinum, and carboplatin versus cisplatin-based chemotherapy in women with advanced ovarian cancer.

Search strategy: Search strategy: We searched MEDLINE, and CancerLit bibliographic databases and the National Cancer Institute and the UK Co-ordinating Committee on Cancer Research registers of trials. We also handsearched the proceedings of meetings and contacted experts in the field and drug companies.

Selection criteria: Randomised trials of: (1) single non-platinum versus non-platinum combination chemotherapy (2) single non-platinum versus platinum combination chemotherapy (3) non-platinum regimen versus the same regimen plus cisplatin (4) single platinum versus platinum combination chemotherapy (5) cisplatin versus carboplatin-based chemotherapy in women with advanced ovarian cancer.

Data collection and analysis: Individual patient data were obtained from the trial investigators, checked by the reviewers and finally verified by the trial investigator.

Main results: Main results: 49 trials involving 8763 women were included. The data were combined to calculate hazard ratios (HR) for survival on an intention-to-treat basis. For single non-platinum versus platinum combination chemotherapy the overall HR for survival was 0.93, 95% confidence interval (CI) 0.83-1.05 in favour of platinum-based combination chemotherapy. For non-platinum regimens compared with the same regimen plus cisplatin the survival HR was 0.88, 95% CI 0.79- 0.98 in favour of the addition of platinum to drug regimens. Single platinum compared with platinum combination therapy gave a HR of 0.91, 95% CI 0.79-1.05 in favour of combination chemotherapy. Cisplatin versus carboplatin gave a HR of 1.02, 95% CI 0.93-1.12. Sub-group analyses for age, stage, grade, histology, resection, bulk of residual tumour and performance status were undertaken for cisplatin versus carboplatin only. No difference in effect was found.

Reviewer's conclusions: The available evidence, although not conclusive, suggests that platinum-based chemotherapy is better than non-platinum therapy. There is some evidence that combination therapy improves survival compared with platinum alone. No difference in effect has been shown between cisplatin and carboplatin.

PubMed Disclaimer

Conflict of interest statement

There is no known conflict of interest

Figures

1.1
1.1. Analysis
Comparison 1 single vs combination non‐platinum, Outcome 1 survival.
2.1
2.1. Analysis
Comparison 2 single non‐platinum vs platinum combination, Outcome 1 survival.
3.1
3.1. Analysis
Comparison 3 non‐platinum vs same regimen + platinum, Outcome 1 survival.
4.1
4.1. Analysis
Comparison 4 single platinum vs platinum combination, Outcome 1 survival.
5.1
5.1. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 1 survival.
5.2
5.2. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 2 Age subgroup.
5.3
5.3. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 3 Stage subgroup.
5.4
5.4. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 4 Grade subgroup.
5.5
5.5. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 5 Performance status subgroup.
5.6
5.6. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 6 Residual bulk subgroup.
5.7
5.7. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 7 Extent of operation subgroup.
5.8
5.8. Analysis
Comparison 5 carboplatin versus cisplatin, Outcome 8 Histology subgroup.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

a Copenhagan {published and unpublished data}
    1. Aabo K, Hald I, Horbov S, Dombernowsky P, Hansen H, Sorensen H, et al. A randomised study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. European Journal of Cancer and Clinical Oncology 1985;21:475‐81. - PubMed
a ECOG E1172 {published and unpublished data}
    1. Brodovsky HS, Bauer M, Horton J, Elson PJ. Comparison of melphalan with cyclophosphamide, methotrexate and 5‐fluorouracil in patients with ovarian cancer. Cancer 1984;53:844‐52. - PubMed
a ECOG E2875 {published and unpublished data}
    1. Bruckner H, Pagano M, Falkson G, Creech R, Arseneau J, Horton H, et al. Controlled prospective trial of combination chemotherapy with cyclophosphamide, Adriamycin and 5‐fluorouracil for the treatment of advanced ovarian cancer: a preliminary report. Cancer Treatment Reports 1979;63:297‐9. - PubMed
a GOG22 {published and unpublished data}
    1. Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum H, Homesley H, et al. A randomised comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983;51:783‐9. - PubMed
a GOG3 {published and unpublished data}
    1. Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5‐fluorouracil and dactinomycin or with the combination of Cytoxan, 5‐fluorouracil and dactinomycin. Cancer 1980;45:2529‐42. - PubMed
a Mayo Clinic 703015 {published and unpublished data}
    1. Edmonson JH, Flemming TR, Decker DG, Malkasian G, Jorgensen E, Jefferies J, et al. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treatment Reports 1979;61:355‐7. - PubMed
a MD Anderson 1974a {published and unpublished data}
    1. Wharton JT, Edwards CL, Rutledge FN. Long‐term survival after chemotherapy for advanced epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1984;148:997‐1005. - PubMed
a MD Anderson 1974b {published and unpublished data}
    1. Wharton JT, Edwards CL, Rutledge FN. Long‐term survival after chemotherapy for advanced epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1984;148:997‐1005. - PubMed
a Milan {published and unpublished data}
    1. Bolis G, Bortolozzi G, Carinelli G, et al. Low‐dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. Cancer Chemotherapy and Pharmacology 1980;4:129‐32. - PubMed
a MRC 1976 {published and unpublished data}
    1. Medical Research Council Working Party on Ovarian Cancer. Medical Research Council study on chemotherapy in advanced ovarian cancer. British Journal of Obstetrics and Gynaecology 1981;88:1174‐85. - PubMed
a NCICCTC OV1 {published and unpublished data}
    1. Miller A, Klaassen DJ, Boyes DA, Dodds D, Gerlath, Kirk M, et al. Combination v sequential therapy with melphalan, 5‐fluorouracil and methotrexate for advanced ovarian cancer. Canadian Medical Association Journal 1980;123:363‐71. - PMC - PubMed
a NCOG5091 {published and unpublished data}
    1. Turbow MM, Jones H, Yu VK, Greenberg B, Hannigan J, Torti FM. Chemotherapy of ovarian carcinoma: a comparison of melphalan vs Adriamycin‐cyclophosphamide. Proceedings of the American Association of Cancer Research and American Society of Clinical Oncology. 1980; Vol. 21:196 Abstract 785.
a SCOCG 1979 {published and unpublished data}
    1. Tropé C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstetrics and Gynecology 1987;70:582‐6. - PubMed
a Zagreb {published and unpublished data}
    1. Chylak V, Kolaric K, Krusic K. Controlled clinical trial of chemotherapy in advanced ovarian cancer ‐ cyclophosphamide mono‐chemotherapy versus a combination of Adriamycin, cyclophosphamide, 5‐fluorouracil and methotrexate. Lijec Vjesen 1986;109:230‐4. - PubMed
a/b Princess Margare {published and unpublished data}
    1. Sturgeon JFG, Fine S, Gospodarowicz MK, Dembo AJ, Bean HA, Bush RS, et al. A randomised trial of melphalan alone vs combination chemotherapy in advanced ovarian cancer. Proceedings of the American Society for Clinical Oncology. 1982; Vol. 1:abstract C‐148.
a/b/c MRC 1981 {unpublished data only}
    1. Medical Research Council Gynaecological Cancer Working Party. Inadequacy of trials of chemotherapy in advanced ovarian carcinoma: a randomised trial of three regimens. a randomised trial of three regimens. (unpublished).
b COSA 1978 {published and unpublished data}
    1. Bell Dr, Woods RK, Levi JA, Fox RM, Tattersall MHN. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cisdiamminedichloroplatinum. Australian and New Zealand Journal of Medicine 1982;12:245‐9. - PubMed
b ECOG EST2878 {published and unpublished data}
    1. Wadler S, Yeap B, Vogl S, Carbone P. Randomised trial of initial therapy with melphalan versus cisplatin‐based combination chemotherapy in patients with advanced ovarian cancer: initial and long‐term results: Eastern Cooperative Oncology Study Group E2878. Cancer 1996;77:733‐42. - PubMed
b Edinburgh {published and unpublished data}
    1. Leonard RC, Smart GE, Livingstone JRB, Cornbleet MA, Kerr GR, Fletcher S, et al. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. Cancer Chemotherapy and Pharmacology 1989;23:105‐110. - PubMed
b MOCCSG 1980 {unpublished data only}
    1. Crowther D. A randomised trial of chemotherapy in advanced residual (stage Iib‐IV) ovarian cancer. Manchester Ovarian Cancer Clinical Study Group protocol, 1996.
b Southampton {published and unpublished data}
    1. Williams CJ, Mead GM, Macbeth FR, Thompson J, Whitehouse JMA, MacDonald H, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomised trial. Journal of Clinical Oncology 1985;3:1455‐62. - PubMed
b/c COSA 1979 {published and unpublished data}
    1. Gynaecological Group, Clinial Oncological Society of Australia and the Sydney Branch, Ludwig Institute for Cancer Research. Chemotherapy of advanced ovarian adenocarcinoma: a randomised comparison of combination versus sequential therapy using chlorambucil and cisplatin. Gynecologic Oncology 1986;23:1‐13. - PubMed
b/c Leo Laboratories {published and unpublished data}
    1. Masding J, Sarkar T, White JF, Barley VL, Chawla SL, Boesen T, et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. British Journal of Obstetrics and Gynaecology 1990;97:342‐51. - PubMed
b/c Loma Linda {published and unpublished data}
    1. Wilbur DW, Rentschler RE, Wagner RJ, Keeney ED, King A, Hilliard DA. Randomised trial of the addition of cisplatin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma. Journal of Surgical Oncology 1987;34:165‐9. - PubMed
b/c OCSG 77‐61‐02 {published and unpublished data}
    1. Decker DG, Thomas MD, Fleming R, Malkesian GD, Webb MD, Jefferies JA, et al. Cyclophosphamide plus cisplatinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstetrics and Gynecology 1982;60:418‐27. - PubMed
c EORTC 55731 {published and unpublished data}
    1. Oliveira CF, Lacave AJ, Villani C, Wolff JP, Re F, Namer M, et al. Randomised comparison of cyclophosphamide, doxorubicin and cisplatin for the treatment of advanced ovarian cancer. European Journal of Gynaecological Oncology 1990;11:323‐30. - PubMed
c GOG 47 {published and unpublished data}
    1. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A randomised trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725‐30. - PubMed
c NCOG 5091 {unpublished data only}
    1. Turbow MM. Chemotherapy of advanced ovarian cancer: Adriamycin‐cyclophosphamide versus platinum‐Adriamycin‐cyclophosphamide. Norther California Oncology Group protocol 5091, 1980. Adriamycin‐cyclophosphamide versus platinum‐Adriamycin‐cyclophosphamide. Norther California Oncology Group protocol 5091, 1980. (unpublished).
c SCOCSG 1981 {published and unpublished data}
    1. Trope C, Anderson H, Björkholm E, Frankendal B, Himmelman A, Högberg T, et al. Doxorubicin‐melphalan with and without cisplatin in advanced ovarian cancer. Ten‐year survival results from a prospective randomised study by the Swedish Cooperative Ovarian Cancer Study Group. Acta Oncologica 1996;35:109‐18. - PubMed
d GICOG 1980 {published and unpublished data}
    1. GICOG. Long‐term results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide and adriamycin in advanced ovarian cancer. Gynecologic Oncology 1992;45:115‐17. - PubMed
d HECOG 1987 {published and unpublished data}
    1. Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, et al. Carbo alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Cooperative Oncology Study Group. European Journal of Cancer 1996;32:421‐8. - PubMed
d Milan {published and unpublished data}
    1. Tomirotti M, Perrone S, Gie P, Canaletti R, Carpi A, Biasoli R, et al. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III‐IV epithelial ovarian carcinoma: a prospective randomised trial. Tumori 1988;74:573‐7. - PubMed
d Mount Sinai {published and unpublished data}
    1. Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, et al. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end‐staging (second‐look) operation. American Journal of Obstetrics and Gynecology 1983;145:955‐65. - PubMed
d Piraeus {published and unpublished data}
    1. Athanassiou A, Pectasides D, Varthalitis J, Barbounis V, Dimitriadis M, et al. Carboplatin (C) versus C + ifosfamide (I) + vincristine (V) + bleomycin (B) in epithelial ovarian cancer (OC). Annals of Oncology 1990;1:2‐25 (suppl).
d Royal Marsden 1979 {published and unpublished data}
    1. Wiltshaw E, Evans B, Rustin G, Gilbey E, Baker J, Barker G. A prospective randomised trial comparing high‐dose cisplatin with low‐dose cisplatin and chlorambucil in advanced ovarian carcinoma. Journal of Clinical Oncology 1986;4:722‐9. - PubMed
d SGCTG 1986 {published and unpublished data}
    1. Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, et al (1992). A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. British Journal of Cancer 61992;5:275‐81. - PMC - PubMed
d UK South West a {unpublished data only}
    1. Gilby E, Pollard W, Bamford D, Barley V, Jelen I, Hale BT, et al. Ovarian Cancer Trial, 1986. Southwest Oncology Study.
d UK South West b {unpublished data only}
    1. Gilby E, Pollard W, Bamford D, Barley V, Jelen I, Hale BT, et al. Ovarian Cancer Trial, 1986. Southwest Oncology Study.
e Athens {published and unpublished data}
    1. Gennatas C, Alamanos J, Dardoufas C, Kovaris J, Androulakis G. Carboplatin, epirubicin and cyclophosphamide versus cisplatin, epirubicin and cyclophosphamide: a phase III randomised trial in stages III and IV epithelial ovarian cancer. Proceedings of the American Society for Clinical Oncology. 1992; Vol. 11:720.
e EORTC 55836 {published and unpublished data}
    1. Bokkel Huinik WW, Burg ME, Oosterom AT, Neijt JP, George M, Gustalla JP, et al. Carboplatin in combination chemotherapy for ovarian cancer. Cancer Treatment Reviews 1988;15:9‐15 (suppl). - PubMed
e GICOG 1984 {published and unpublished data}
    1. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, et al. Randomised trial in advanced ovarian cancer comparing cisplatin and carboplatin. Jounal of the National Cancer Institute 1989;81:1464‐71. - PubMed
e GOCA {published and unpublished data}
    1. Meerpohl HG, Kuhnle J, Sauerbrei W, Achterrach W, Pfeiderer A (1990). Cyclophosphamide/cisplatin (CTX/PT) cs CTX/carboplatin (CarboPT) in advanced ovarian carcinoma: a randomised multicentre study. 1120.
e GONO {published and unpublished data}
    1. Conte PF, Bruzzone M, Carnin F, Chiara S, Donadio M, Facchini V, et al. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomised trial in stage III‐IV epithelial ovarian carcinoma. Journal of Clinical Oncology 1991;9:658‐63. - PubMed
e Japan {published and unpublished data}
    1. Kato T, Nishimura H, Yamabe T, Terashima Y, Kasamatsu T, Hirabayashi K, et al. Phase III study of carboplatin for ovarian cancer. Japanese Journal of Cancer Chemotherapy 1988;15:2297‐304. - PubMed
e Mayo Clinic 846151 {published and unpublished data}
    1. Edmonson JH, McCormack Gm, Wieand HS, Kugler HW, Krook JE, Stanhope CR, et al (1989). Cyclophosphamide‐cisplatin versus cyclophosphamide‐carboplatin in stage III‐IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. Journal of the National Cancer Institute 1989;81:1500‐4. - PubMed
e MOCCSG 1984 {published and unpublished data}
    1. Anderson H, Wagstaff J, Crowther D, Evans A, Johansen K, Franks CR. Comparitive toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. European Journal Cancer and Clinical Oncology 1988;24:1471‐9. - PubMed
e NCIC CTC 0v.8 {published and unpublished data}
    1. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, et al. Cisplatin ‐ cyclophosphamide versus carboplatin‐cyclophosphamide in advanced ovarian cancer: a randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1992;10:718‐26. - PubMed
e Royal Marsden 1981 {published and unpublished data}
    1. Taylor AE, Wiltshaw E, Gore M, Fryatt I, Fisher C. Long‐term follow up of the first randomised study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. Journal of Clinical Oncology 1994;12:2066‐70. - PubMed
e SWOG 8412 {published and unpublished data}
    1. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock‐Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomised trial in stages III and IV ovarian cancer. Journal of Clinical Oncology 1992;10:706‐17. - PubMed
e Wales {published and unpublished data}
    1. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR (1989). A comparison of toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncologia 1989;28:57‐60. - PubMed

References to studies excluded from this review

Adams 1982 {published data only}
    1. Adams M, Johansen KA, James KW, Rocker I. A controlled clinical trial in advanced ovarian cancer. Clinical Radiology 1982;33:161‐3. - PubMed
Barlow 1985 {published data only}
    1. Barlow JJ, Lele SB, Emrich LJ. Long‐term survival rates with various chemotherapeutic regimens in stage III and IV ovarian adenocarcinoma. American Journal of Obstetrics and Gynecology 1985;152:310‐4. - PubMed
Belpomme 1992 {published data only}
    1. Belpomme D, Bugat R, Rives M, Pinon G, Roullet B, Facchini T, et al. Carboplatin versus cisplatin as first line therapy in stage III‐IV ovarian carcinoma: results of an ARTAC phase III trial. 722.
Carmo‐Pereira 1981 {published data only}
    1. Carmo‐Pereira J, Oliveira Costa F, Henriques E, Almeida Ricardo J. Advanced ovarian carcinoma: a prospective and randomised clinical trial of cyclophosphamide vs combination cytotoxic chem (Hexa‐CAF). Cancer 1981;48:1947‐51. - PubMed
Carmo‐Pereira 1983 {published data only}
    1. Carmo‐Pereira J, Oliveira Costa F, Henriques E. Cis‐platinum, Adriamycin and hexamethylmelamine vs cyclophosphamide in advanced ovarian carcinoma. Cancer Chemotherapy and Pharmacology 1983;10:100‐3. - PubMed
De Palo 1977 {published data only}
    1. Palo G, Lena M, Bonadonna G. Adriamycin vs Adriamycin plus melphalan in advanced ovarian carcinoma. Cancer Treatment Reports 1977;61:355‐7. - PubMed
Delgado 1985 {published data only}
    1. Delgado G, Smith FP, McLaughlin Ek, Tuholski N. Single agent vs combination chemotherapy for ovarian cancer. American Journal of Clinical Oncology 1985;8:33‐7. - PubMed
Gronroos 1984 {published data only}
    1. Gronroos M, Nieminen U, Kauppila A, Kauppila O, Saksela E, Vayrynen M. A prospective randomised national trial for treatment of ovarian cancer: the role of chemotherapy and external radiation. European Journal of Obstetrics Gynecology and Reproductive Biology 1984;17:33‐42. - PubMed
Harvey 1982 {published data only}
    1. Harvey HA, Lipton A, Simmonds M, White D, Gottloeb R, Bernath A, et al. A randomised trial of Alkeran versus cyclophosphamide, hexamethylmelamine. Adriamycin and cisplatin combination chemotherapy in advanced ovarian carcinoma. Clinical research 1982;30:418.
Senn 1980 {published data only}
    1. Senn HJ, Lei D, Castano‐Almendral A, Brunner K, Martz G, Obrecht P, et al. Chemo‐mormono therapy for FIGO stage III and IV ovarian cancer. prospective SAKK study 20/77 [Chemo‐(hormon)‐therapie fortgeschrittener ovarialkarzinome der FIGO‐stadien III and IV. Prospective SAKK‐studie 20/71]. Schweizerische medizinische Wochenschrift 1980;110:1202‐8. - PubMed
Young 1978 {published data only}
    1. Young RC, Chabner BA, Hubbard SP, Fisher R, Bender R, Anderson T, et al. Advanced ovarian carcinoma: a prospective clinical trial of melphalan (L‐PAM) versus combination chemotherapy. The New England journal of medicine 1978;299:1261‐6. - PubMed

Additional references

Bajorin et al 1993
    1. Bajorin D, Sarosdy MF, Poster DG, et al. Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good‐risk germ cell tumours. A Multi‐institutional study. Journal of Clinical Oncology 1993;11:598‐606. - PubMed
Freedman 1982
    1. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine 1982;1:121‐129. - PubMed
Horwich et al 1994
    1. Horwich A, Sleijfer D, Fossa S, et al. A trial of carboplatin‐based chemotherapy in good prognosis metastatic testicular non seminoma. Proceedings of the American Society of Clinical Oncology 1994;13:231 (abstract 709).
OCMP 1991
    1. Ovarian Cancer Meta‐analysis Project. CP versus CAP chemotherapy of ovarian carcinoma: a meta‐analysis. Journal of Clinical Oncology 1991;9:1669‐1679. - PubMed
Parkin et al 1980
    1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. International Journal of Cancer 1988;41:184‐97. - PubMed
Torri 1996
    1. Torri V on behalf of the International Ovarian Neoplasm Studies. Randomised study of cyclophosphamide, doxorubicin and cisplatin (CAP) vs single‐agent carboplatin in ovarian cancer patients requiring chemotherapy: interim results of ICON2. Proceedings of the American Society of Clinical Oncology. 1996; Vol. 15:752.
Yusuf et al 1985
    1. Yusuf S, Peto R, Lewis J, Collins R, Sleight T. Beta blockade during and after myocardial infarction: an overview of randomised clinical trials. Progress in Cardiovascular Disease 1985;27:335‐71. - PubMed

References to other published versions of this review

AOCTG 1991
    1. Advanced Ovarian cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991;303:884‐93. - PMC - PubMed
AOCTG 1998
    1. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta‐analyses of individual patient data from 37 randomised trials. British Journal of Cancer 1998;78:1479‐87. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources